SYS-CON MEDIA Authors: Unitiv Blog, Mark R. Hinkle, Glenn Rossman, Kevin Benedict, Jason Bloomberg

News Feed Item

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update
http://www.reportlinker.com/p02029806/PharmaPoint-Multiple-Sclerosis---Global-Drug-Forecast-and-Market-Analysis-to-2022-Event-Driven-Update.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update

Summary

Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Highlights

Key Questions Answered

- Injectable DMTs dominate the MS market, however unmet needs exist in terms of safety, convenience of administration and efficacy. Will the recently launched drugs or those under development fulfil the unmet needs of the MS market?
- Several major brands of MS drugs are due to lose patent protection during the forecast period. How will these patent expiries impact the MS therapeutics market?
- The late-stage development pipeline consists of several agents that target novel pathways in MS. Which of these pipeline drugs will attain the highest sales revenues during the forecast period?
- In the increasingly competitive MS landscape, how are the key established players and emerging companies looking to maintain or enhance their presence on the MS market?

Key Findings

- Big pharmaceutical companies and smaller biotech companies with no previous involvement in the MS space are developing promising pipeline drugs to capitalize on the lucrative MS market.
- Key patent expiries to several leading MS drugs, including Copaxone will negatively impact the growth of the MS market due to significant brand erosion.
- The anticipated launch of several pipeline oral products and the continued success of currently marketed oral MS drugs, such as Gilenya, are expected to progressively diminish the use of established injectable therapies.
- The emergence of pipeline MS drugs that specifically target progressive MS will drive up treatment rates in the currently underserved population of patients with secondary-progressive MS and primary-progressive MS.

Scope

- Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized MS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2011 and forecast through to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including B cell-based therapies, second generation IFNß agents and S1P receptor modulators, kinase inhibitors, MS vaccines, and agents that target novel pathways in MS, such as Nrf-2 and IL-2.
- Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products , and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
- Drive revenues by understanding the key trends, innovative products, market segments, and companies likely to impact the global MS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global MS therapeutics market from 2011-2022
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 21
2.1 Catalyst 21
2.2 Upcoming Related Reports 22
3 Disease Overview 23
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23

3.1.2 Pathophysiology 24
3.1.3 Classification of Multiple Sclerosis 25
3.2 Symptoms 27
3.2.1 Prognosis 28
3.2.2 Quality of Life 29
4 Epidemiology 30
4.1 Risk Factors 30
4.1.1 Family members of MS patients have a 1-5% risk of developing MS 30
4.1.2 Women are twice as likely to develop MS, but men have a worse prognosis 30
4.1.3 Caucasians have a higher risk of MS than any other race/ethnicity 31
4.1.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 31
4.1.5 Timing of environmental exposures affects MS risk 32
4.1.6 Exposure to smoking may increase MS risk and worsen prognosis 32
4.2 Comorbidities 33
4.2.1 Autoimmune diseases may be comorbidities of MS 33
4.2.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 34
4.3 Global Trends 35
4.3.1 North America 35
4.3.2 Europe 36
4.3.3 Asia 36
4.4 Forecast Methodology 37
4.4.1 Sources Used 39
4.4.2 Forecast Assumptions and Methods 45
4.4.3 Sources Not Used 54
4.5 Epidemiology Forecast for Multiple Sclerosis 55
4.5.1 Total Prevalent Cases of Multiple Sclerosis 55
4.5.2 Age-Specific Prevalent Cases of Multiple Sclerosis 57
4.5.3 Gender-Specific Prevalent Cases of Multiple Sclerosis 59
4.5.4 Total Incident Cases of Multiple Sclerosis 61
4.5.5 Age-Specific Incident Cases of Multiple Sclerosis 63

4.5.6 Gender-Specific Incident Cases of Multiple Sclerosis 65
4.5.7 Multiple Sclerosis Subtypes 67
4.6 Discussion 68
4.6.1 Conclusions on Epidemiological Trends 68
4.6.2 Limitations of the Analysis 69
4.6.3 Strengths of the Analysis 69
5 Disease Management 70
5.1 Diagnosis 70
5.2 Treatment Overview 73
5.2.1 Management of Acute Relapse 74
5.2.2 Treatment with Disease-Modifying Therapies 74
5.2.3 Symptomatic Therapies 77
5.3 US 78
5.3.1 Diagnosis 78
5.3.2 Clinical Practice 78
5.4 France 80
5.4.1 Diagnosis 80
5.4.2 Clinical Practice 80
5.5 Germany 82
5.5.1 Diagnosis 82
5.5.2 Clinical Practice 82
5.6 Italy 84
5.6.1 Diagnosis 84
5.6.2 Clinical Practice 84
5.7 Spain 85
5.7.1 Diagnosis 85
5.7.2 Clinical Practice 85
5.8 UK 87
5.8.1 Diagnosis 87
5.8.2 Clinical Practice 87
5.9 Japan 89
5.9.1 Diagnosis 89
5.9.2 Clinical Practice 89
5.10 Canada 90
5.10.1 Diagnosis 90
5.10.2 Clinical Practice 90
5.11 China 91
5.11.1 Diagnosis 91

5.11.2 Clinical Practice 91
5.12 India 92
5.12.1 Diagnosis 92
5.12.2 Clinical Practice 92
6 Competitive Assessment 94
6.1 Overview 94
6.2 Strategic Competitor Assessment 95
6.3 Product Profiles - Major Brands 97
6.3.1 Betaseron/Betaferon (interferon beta-1b) 97
6.3.2 Avonex (interferon beta-1a) 103
6.3.3 Rebif (interferon beta-1a) 109
6.3.4 Copaxone (glatiramer acetate; copolymer-1) 114
6.3.5 Tysabri (natalizumab) 120
6.3.6 Gilenya/Imusera (fingolimod; FTY720) 126
6.3.7 Aubagio (teriflunomide) 132
6.3.8 Other Disease-Modifying Therapies 138
7 Opportunity and Unmet Need 139
7.1 Overview 139
7.2 Unmet Needs 140
7.2.1 Currently Available MS Drugs Only Provide Partial Benefits 140
7.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 141
7.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 142
7.2.4 Effective Treatments for Progressive MS Are Still Elusive 143
7.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 144
7.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 145
7.3 Unmet Needs Gap Analysis 146
7.4 Opportunities 148
7.4.1 Treatments for Progressive MS 148
7.4.2 Targeting Patients with Clinically Isolated Syndrome 148
8 Pipeline Assessment 149

8.1 Overview 149
8.2 Clinical Trial Mapping 151
8.2.1 Clinical Trials by Country 151
8.3 Clinical Trials by Phase and Trial Status 152
8.4 Promising Drugs in Clinical Development 153
8.4.1 Tecfidera (dimethyl fumarate) 155
8.4.2 Lemtrada (alemtuzumab) 161
8.4.3 Laquinimod (ABR-215062) 168
8.4.4 Daclizumab High-Yield Process (HYP) 175
8.4.5 Ocrelizumab (RG1594) 181
8.4.6 Siponimod (BAF-312) 187
8.4.7 NU-100 (interferon beta-1b) 193
8.4.8 Masitinib (AB-1010) 198
8.4.9 Tcelna (imilecleucel-T) 203
9 Current and Future Players 208
9.1 Overview 208
9.2 Trends in Corporate Strategy 210
9.3 Company Profiles 212
9.3.1 Biogen Idec 212
9.3.2 Teva Pharmaceutical Industries 215
9.3.3 Merck Serono (EMD Serono) 218
9.3.4 Sanofi 221
9.3.5 Bayer HealthCare Pharmaceuticals 224
9.3.6 Novartis International 226
9.3.7 Hoffmann-La Roche 229
9.3.8 GlaxoSmithKline 231
10 Market Outlook 233
10.1 Global Markets 233
10.1.1 Forecast 233
10.1.2 Drivers and Barriers - Global Issues 236
10.2 United States 240
10.2.1 Forecast 240
10.2.2 Key Events 244
10.2.3 Drivers and Barriers 244

10.3 France 247
10.3.1 Forecast 247
10.3.2 Key Events 251
10.3.3 Drivers and Barriers 251
10.4 Germany 254
10.4.1 Forecast 254
10.4.2 Key Events 258
10.4.3 Drivers and Barriers 258
10.5 Italy 261
10.5.1 Forecast 261
10.5.2 Key Events 264
10.5.3 Drivers and Barriers 264
10.6 Spain 267
10.6.1 Forecast 267
10.6.2 Key Events 271
10.6.3 Drivers and Barriers 271
10.7 United Kingdom 273
10.7.1 Forecast 273
10.7.2 Key Events 277
10.7.3 Drivers and Barriers 277
10.8 Japan 280
10.8.1 Forecast 280
10.8.2 Key Events 283
10.8.3 Drivers and Barriers 283
10.9 Canada 285
10.9.1 Forecast 285
10.9.2 Key Events 289
10.9.3 Drivers and Barriers 289
10.10 China 291
10.10.1 Forecast 291
10.10.2 Key Events 294
10.10.3 Drivers and Barriers 295
10.11 India 297
10.11.1 Forecast 297
10.11.2 Key Events 299
10.11.3 Drivers and Barriers 300

11 Appendix 302
11.1 Bibliography 302
11.2 Abbreviations 320
11.3 Methodology 324
11.4 Forecasting Methodology 324
11.4.1 Diagnosed MS patients 324
11.4.2 Percent Drug-Treated Patients 325
11.4.3 Drugs Included in Each Therapeutic Class 325
11.4.4 Launch and Patent Expiry Dates 326
11.4.5 General Pricing Assumptions 327
11.4.6 Individual Drug Assumptions 328
11.4.7 Generic Erosion 332
11.4.8 Pricing of Pipeline agents 332
11.5 Physicians and Specialists Included in This Report 334
11.6 Primary Research - Prescriber Survey 335
11.7 About the Authors 336
11.7.1 Analysts 336
11.7.2 Epidemiologists 337
11.7.3 Global Head of Healthcare 337
11.8 About GlobalData 338
11.9 Contact Us 338
11.10 Disclaimer 338

List of Tables

Table 1: Common Presenting Symptoms of Multiple Sclerosis 27
Table 2: Factors That Can Affect Prognosis in Multiple Sclerosis 28
Table 3: Sources of Prevalence and Incidence Data Used in the Epidemiology Forecast 38
Table 4: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ?20, Male and Female, N, Select 56
Table 5: 10 Markets, Prevalent Cases of Multiple Sclerosis, By Age*, Male and Female, N (Row %), 2012 57
Table 6: 10 Major Markets, Prevalent Cases of Multiple Sclerosis, Ages ?20, By Gender, N (Row %), 2012 59
Table 7: 10 Markets, Incident Cases of Multiple Sclerosis, Ages ?20, Male and Female, N, Select Years, 2012-2022 62
Table 8: 10 Markets, Incident Cases of Multiple Sclerosis, By Age*, Male and Female, N (Row %), 2012 63
Table 9: 10 Major Markets, Incident Cases of Multiple Sclerosis, By Gender, N (Row %), 2012 65
Table 10: Revised 2010 McDonald Criteria for the Diagnosis of Multiple Sclerosis 71
Table 11: Treatment Guidelines for Multiple Sclerosis 73
Table 12: Top Three Disease-Modifying Therapies Prescribed for Multiple Sclerosis by Market 75
Table 13: Pharmacotherapy for Common Multiple Sclerosis Symptoms 77
Table 14: Disease-Modifying Drugs for the Treatment of Multiple Sclerosis, 2012 96
Table 15: Product Profile - Betaseron 98
Table 16: Betaseron/Betaferon SWOT Analysis, 2012 101
Table 17: Global Sales Forecasts ($m) for Betaseron/Betaferon, 2012-2022 102
Table 18: Product Profile - Avonex 104
Table 19: Avonex SWOT Analysis, 2012 107
Table 20: Global Sales Forecasts ($m) for Avonex, 2012-2022 108
Table 21: Product Profile - Rebif 110
Table 22: Rebif SWOT Analysis, 2012 112
Table 23: Global Sales Forecasts ($m) for Rebif, 2012-2022 113

Table 24: Product Profile - Copaxone 115
Table 25: Copaxone SWOT Analysis, 2012 118
Table 26: Global Sales Forecasts ($m) for Copaxone, 2012-2022 119
Table 27: Product Profile - Tysabri 121
Table 28: Tysabri SWOT Analysis, 2012 124
Table 29: Global Sales Forecasts ($m) for Tysabri, 2012-2022 125
Table 30: Product Profile - Gilenya 127
Table 31: Gilenya SWOT Analysis, 2012 130
Table 32: Global Sales Forecasts ($m) for Gilenya/Imusera, 2012-2022 131
Table 33: Product Profile - Aubagio 133
Table 34: Aubagio SWOT Analysis, 2012 136
Table 35: Global Sales Forecasts ($m) for Aubagio, 2012-2022 137
Table 36: Summary of Alternative MS DMTs, 2012 138
Table 37: Overall Unmet Needs - Current Level of Attainment 139
Table 38: Clinical Unmet Needs - Gap Analysis, 2012 147
Table 39: Multiple Sclerosis - Clinical Trials by Phase and Status, 2012 152
Table 40: Multiple Sclerosis - Phase IIb/III Pipeline, 2012 153
Table 41: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 154
Table 42: Product Profile - Tecfidera 156
Table 43: Tecfidera SWOT Analysis, 2012 159
Table 44: Global Sales Forecasts ($m) for Tecfidera, 2012-2022 160
Table 45: Product Profile - Lemtrada 162
Table 46: Lemtrada SWOT Analysis, 2012 166
Table 47: Global Sales Forecasts ($m) for Lemtrada, 2012-2022 167
Table 48: Product Profile - Laquinimod 169
Table 49: Laquinimod SWOT Analysis, 2012 173
Table 50: Global Sales Forecasts ($m) for Laquinimod, 2012-2022 174

Table 51: Product Profile - Daclizumab High-Yield Process 176
Table 52: Daclizumab SWOT Analysis, 2012 179
Table 53: Global Sales Forecasts ($m) for Daclizumab, 2012-2022 180
Table 54: Product Profile - Ocrelizumab 182
Table 55: Ocrelizumab SWOT Analysis, 2012 185
Table 56: Global Sales Forecasts ($m) for Ocrelizumab, 2012-2022 186
Table 57: Product Profile - Siponimod 188
Table 58: Siponimod SWOT Analysis, 2012 191
Table 59: Global Sales Forecasts ($m) for Siponimod, 2012-2022 192
Table 60: Product Profile - NU-100 194
Table 61: NU-100 SWOT Analysis, 2012 196
Table 62: Global Sales Forecasts ($m) for NU-100, 2012-2022 197
Table 63: Product Profile - Masitinib 198
Table 64: Masitinib SWOT Analysis, 2012 201
Table 65: Global Sales Forecasts ($m) for Masitinib, 2012-2022 202
Table 66: Product Profile - Tcelna 204
Table 67: Tcelna SWOT Analysis, 2012 206
Table 68: Global Sales Forecasts ($m) for Tcelna, 2012-2022 207
Table 69: Key Companies in the Multiple Sclerosis Market, 2012 209
Table 70: Biogen's Multiple Sclerosis Portfolio Assessment, 2012 213
Table 71: Biogen SWOT Analysis, 2012 214
Table 72: Teva's Multiple Sclerosis Portfolio Assessment, 2012 216
Table 73: Teva SWOT Analysis, 2012 217
Table 74: Merck's Multiple Sclerosis Portfolio Assessment, 2012 219
Table 75: Merck SWOT Analysis, 2012 220
Table 76: Sanofi's Multiple Sclerosis Portfolio Assessment, 2012 222
Table 77: Sanofi SWOT Analysis, 2012 223
Table 78: Bayer's Multiple Sclerosis Portfolio Assessment, 2012 225

Table 79: Bayer SWOT Analysis, 2012 225
Table 80: Novartis' Multiple Sclerosis Portfolio Assessment, 2012 227
Table 81: Novartis SWOT Analysis, 2012 228
Table 82: Roche's Multiple Sclerosis Portfolio Assessment, 2012 230
Table 83: Roche SWOT Analysis, 2012 230
Table 84: GlaxoSmithKiline's Multiple Sclerosis Portfolio Assessment, 2012 232
Table 85: GlaxoSmithKline SWOT Analysis, 2012 232
Table 86: Global Sales Forecasts ($m) for Multiple Sclerosis, 2012-2022 234
Table 87: Global Multiple Sclerosis Market - Drivers and Barriers, 2012 236
Table 88: Sales Forecasts ($m) for Multiple Sclerosis in the United States, 2012-2022 242
Table 89: Key Events Impacting Sales for Multiple Sclerosis the United States, 2012 244
Table 90: Multiple Sclerosis Market in the United States - Drivers and Barriers, 2012 244
Table 91: Sales Forecasts ($m) for Multiple Sclerosis in France, 2012-2022 249
Table 92: Key Events Impacting Sales for Multiple Sclerosis in France, 2012 251
Table 93: Multiple Sclerosis Market in France - Drivers and Barriers, 2012 251
Table 94: Sales Forecasts ($m) for Multiple Sclerosis in Germany, 2012-2022 256
Table 95: Key Events Impacting Sales for Multiple Sclerosis in Germany, 2012 258
Table 96: Multiple Sclerosis Market in Germany - Drivers and Barriers, 2012 258
Table 97: Sales Forecasts ($m) for Multiple Sclerosis in Italy, 2012-2022 262
Table 98: Key Events Impacting Sales for Multiple Sclerosis in Italy, 2012 264
Table 99: Multiple Sclerosis Market in Italy - Drivers and Barriers, 2012 264
Table 100: Sales Forecasts ($m) for Multiple Sclerosis in Spain, 2012-2022 269
Table 101: Key Events Impacting Sales for Multiple Sclerosis in Spain, 2012 271
Table 102: Multiple Sclerosis Market in Spain - Drivers and Barriers, 2012 271
Table 103: Sales Forecasts ($m) for Multiple Sclerosis in the United Kingdom, 2012-2022 275
Table 104: Key Events Impacting Sales for Multiple Sclerosis in the United Kingdom, 2012 277
Table 105: Multiple Sclerosis Market in the United Kingdom - Drivers and Barriers, 2012 277
Table 106: Sales Forecasts ($m) for Multiple Sclerosis in Japan, 2012-2022 281
Table 107: Key Events Impacting Sales for Multiple Sclerosis in Japan, 2012 283

Table 108: Multiple Sclerosis Market in Japan - Drivers and Barriers, 2012 283
Table 109: Sales Forecasts ($m) for Multiple Sclerosis in Canada, 2012-2022 287
Table 110: Key Events Impacting Sales for Multiple Sclerosis in Canada, 2012 289
Table 111: Multiple Sclerosis Market in Canada - Drivers and Barriers, 2012 289
Table 112: Sales Forecasts ($m) for Multiple Sclerosis in China, 2012-2022 292
Table 113: Key Events Impacting Sales for Multiple Sclerosis in China, 2012 294
Table 114: Multiple Sclerosis Market in China - Drivers and Barriers, 2012 295
Table 115: Sales Forecasts ($m) for Multiple Sclerosis in India, 2012-2022 298
Table 116: Key Events Impacting Sales for Multiple Sclerosis in India, 2012 299
Table 117: Multiple Sclerosis Market in India - Drivers and Barriers, 2012 300
Table 118: Key Launch Dates 326
Table 119: Key Patent Expiries 326
Table 120: Physicians Surveyed, By Country 335

1.2 List of Figures
Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis 26
Figure 2: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ?20, Male and Female, N, Select 56
Figure 3: 10 Markets, Prevalent Cases of Multiple Sclerosis, By Age*, Male and Female, N, 2012 58
Figure 4: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ?20, By Gender, N, 2012 60
Figure 5: 10 Markets, Incident Cases of Multiple Sclerosis, Ages ?20, Male and Female, N, Select Years, 2012-2022 62
Figure 6: 10 Markets, Incident Cases of Multiple Sclerosis, By Age*, Male and Female, N, 2012 64
Figure 7: 10 Markets, Incident Cases of Multiple Sclerosis, By Gender, N, 2012 66
Figure 8: 10 Markets, Multiple Sclerosis Subtypes in Prevalent Cases, %*, 2012-2022 67
Figure 9: Expanded Disability Status Scale (EDSS) 72
Figure 10: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies 76
Figure 11: Multiple Sclerosis Therapeutics - Clinical Trials by Country, 2012 151
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012-2022 153
Figure 13: Company Portfolio Gap Analysis in Multiple Sclerosis, 2012-2022 211
Figure 14: Global Market Sales for Multiple Sclerosis by Region, 2012-2022 235
Figure 15: Sales for Multiple Sclerosis in the United States by Drug Class, 2012-2012 243
Figure 16: Sales for Multiple Sclerosis in France by Drug Class, 2012-2012 250
Figure 17: Sales for Multiple Sclerosis in Germany by Drug Class, 2012-2012 257
Figure 18: Sales for Multiple Sclerosis in Italy by Drug Class, 2012-2012 263
Figure 19: Sales for Multiple Sclerosis in Spain by Drug Class, 2012-2012 270
Figure 20: Sales for Multiple Sclerosis in the United Kingdom by Drug Class, 2012-2012 276
Figure 21: Sales for Multiple Sclerosis in Japan by Drug Class, 2012-2012 282
Figure 22: Sales for Multiple Sclerosis in Canada by Drug Class, 2012-2012 288
Figure 23: Sales for Multiple Sclerosis in China by Drug Class, 2012-2012 293
Figure 24: Sales for Multiple Sclerosis in India by Drug Class, 2012-2012 299

To order this report: PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update
http://www.reportlinker.com/p02029806/PharmaPoint-Multiple-Sclerosis---Global-Drug-Forecast-and-Market-Analysis-to-2022-Event-Driven-Update.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.